Listen to this article · 7 min listen

The story of Akili Interactive, once hailed as a pioneer for its FDA-cleared video game therapy, and its subsequent workforce reductions and eventual acquisition, presents a critical case study for investors and clinicians navigating the complex landscape of AI in healthcare. Akili, which had faced significant commercial headwinds including multiple workforce reductions, was acquired by Virtual Therapeutics in May 2024, with the deal closing in July 2024. It prompts a fundamental question: how does a company achieve a landmark regulatory clearance, yet struggle so profoundly with commercial viability? This narrative, paralleled by the similar trajectory of Pear Therapeutics, underscores a vital distinction between regulatory success and market sustainability, highlighting that an FDA clearance, while crucial, does not inherently guarantee a robust safety ecosystem or a clear path to profitability.

The Double-Edged Sword of Pioneering: Akili Interactive and Pear Therapeutics

Akili Interactive made headlines with EndeavorRx, the first prescription video game therapy to receive FDA clearance for treating ADHD in children. This achievement, utilizing the FDA 510(k) Pathway, positioned Akili as a leader in digital therapeutics, demonstrating the potential for novel, software-based interventions. Yet, despite this regulatory milestone, the company faced significant commercial headwinds, culminating in multiple substantial workforce cuts, including a 40% reduction in September 2023 and a further 46-50% reduction in May 2024. This period also saw Akili pivot its strategy from a prescription-based model to a direct-to-consumer, non-prescription approach for its EndeavorOTC product, in an attempt to improve market access and commercial viability. Ultimately, these challenges led to Akili’s acquisition by Virtual Therapeutics. This situation mirrors, in many respects, the fate of Pear Therapeutics, another digital therapeutic pioneer that also secured multiple FDA clearances for its prescription software applications before ultimately filing for bankruptcy. The common thread between Akili and Pear is striking: both companies successfully navigated the stringent regulatory environment of the FDA, gaining clearances for their Software as a Medical Device (SaMD) products. However, their subsequent commercial struggles reveal a critical gap between regulatory validation and market adoption. For investors, this raises questions about the true value proposition of an FDA clearance in a nascent market. Is regulatory de-risking sufficient when reimbursement pathways are unclear, and clinical integration remains challenging? For clinicians, these cases highlight that even clinically validated AI, when not supported by a viable commercial model, struggles to reach the patients who could benefit. The promise of innovative AI-driven therapies, though scientifically sound and regulatorily approved, can falter without a robust ecosystem encompassing payer acceptance, physician buy-in, and patient adherence. As Michael Pencina, a recognized authority in biostatistics and health data science, has often emphasized, the journey from regulatory approval to widespread clinical impact requires more than just efficacy data; it demands a comprehensive understanding of healthcare delivery and economic realities Michael Pencina’s insights on clinical impact. The challenges faced by Akili and Pear suggest that the “safety ecosystem” for AI in healthcare extends far beyond the technical safety and efficacy established by regulatory bodies. It encompasses the entire journey from development to patient access and sustained use. This includes ensuring that the technology integrates seamlessly into existing clinical workflows, that clinicians are adequately trained, and that payers recognize and reimburse its value. Without these elements, even the most innovative and FDA-cleared AI solutions risk becoming “zombie companies”, technologically advanced but commercially stagnant.

Navigating Regulatory Frameworks: FDA 510(k) Pathway and SaMD

The regulatory journey for Akili Interactive and Pear Therapeutics largely involved the FDA 510(k) Pathway, a premarket submission demonstrating that a device is substantially equivalent to a predicate device already legally marketed. This pathway is a cornerstone for many medical devices, including a significant number of AI-driven tools. For SaMD, the FDA has been actively developing frameworks to accommodate the unique characteristics of software, recognizing that these products evolve differently from traditional hardware. The FDA SaMD Framework, specifically developed by the International Medical Device Regulators Forum (IMDRF) and adopted by the FDA, provides guidance on risk classification and quality management systems for software that functions as a medical device. The FDA Center for Devices and Radiological Health (CDRH) plays a pivotal role in this oversight, ensuring that medical devices, including SaMD, are safe and effective. The clearances granted to Akili and Pear were a testament to their ability to meet the rigorous standards set by the FDA CDRH. However, the subsequent commercial difficulties highlight that regulatory compliance, while a necessary condition for market entry, is not a sufficient condition for commercial success or widespread clinical adoption. Investors need to critically assess whether a company’s regulatory strategy aligns with a clear and executable commercialization plan, particularly regarding reimbursement and integration into existing healthcare infrastructure. Clinicians, while reassured by FDA clearance regarding safety and efficacy, must also consider the practicalities of incorporating such technologies into their practice.

The Broader Implication: Clearance Does Not Equal a Sustainable Safety Ecosystem

The experiences of Akili Interactive and Pear Therapeutics serve as a potent reminder that an FDA clearance, while a critical validation of a medical device’s safety and effectiveness, does not automatically translate into a sustainable commercial safety ecosystem. Both companies achieved significant regulatory milestones, demonstrating the potential of digital therapeutics and AI in healthcare. Yet, their subsequent struggles underscore a crucial disconnect: regulatory approval addresses the “what” (is it safe and effective?), but often leaves the “how” (how will it be integrated, paid for, and sustained?) unanswered. For investors, this means that due diligence must extend beyond regulatory status to encompass market access strategies, reimbursement models, and the practicalities of clinical adoption. A “data moat” or innovative technology alone may not suffice if the path to commercialization is fraught with unaddressed challenges. For clinicians, while FDA clearance provides confidence in the scientific rigor, the practical utility and accessibility of these innovations are equally important. The ultimate safety ecosystem for AI in healthcare is not just about preventing harm through regulation; it’s about ensuring that beneficial technologies can genuinely reach and impact patients effectively and sustainably. The cases of Akili and Pear are not failures of the technology itself, nor necessarily of the regulatory process, but rather a stark illustration of the complex interplay between innovation, regulation, and market realities in the evolving landscape of AI in health Analysis of digital therapeutic market challenges.

Frequently Asked Questions

For Investors/VCs: Why did Akili, despite FDA clearance, struggle commercially?

Akili struggled commercially because FDA clearance, while crucial for market entry, did not guarantee market sustainability. The company faced significant commercial headwinds, including unclear reimbursement pathways, challenges with clinical integration, and difficulty securing payer acceptance and physician buy-in. This led to multiple workforce reductions and a pivot from a prescription to a direct-to-consumer model before its acquisition.

For Investors/VCs: What key lesson should investors take from Akili’s acquisition regarding AI in healthcare?

Investors should learn that regulatory de-risking through FDA clearance is not sufficient for commercial success in a nascent market. A comprehensive commercialization plan is essential, addressing reimbursement, integration into existing healthcare infrastructure, and securing payer and physician acceptance. Without these elements, even innovative, FDA-cleared AI solutions risk becoming commercially stagnant.

For Clinicians: What does Akili’s journey tell us about the practical application of FDA-cleared AI therapies?

Akili’s journey highlights that even clinically validated and FDA-cleared AI therapies may struggle to reach patients without a viable commercial model. Practical challenges include seamless integration into clinical workflows, adequate training for clinicians, and payer recognition and reimbursement. Without this ‘safety ecosystem’ beyond regulatory approval, patient access and sustained use are difficult to achieve.

For Clinicians: How should clinicians evaluate FDA-cleared AI solutions beyond their regulatory status?

Clinicians should evaluate FDA-cleared AI solutions not only for their safety and efficacy but also for their practicalities in clinical practice. This includes assessing how well the technology integrates into existing workflows, whether adequate training is available, and if there are clear pathways for patient access and reimbursement. Regulatory compliance is necessary, but not sufficient for widespread clinical adoption.